Agilon Health (AGL) EBIAT (2020 - 2025)
Agilon Health (AGL) has disclosed EBIAT for 6 consecutive years, with -$188.9 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, EBIAT fell 77.55% year-over-year to -$188.9 million, compared with a TTM value of -$405.3 million through Dec 2025, down 61.96%, and an annual FY2025 reading of -$405.3 million, down 61.96% over the prior year.
- EBIAT was -$188.9 million for Q4 2025 at Agilon Health, down from -$110.2 million in the prior quarter.
- Across five years, EBIAT topped out at $16.0 million in Q1 2023 and bottomed at -$298.9 million in Q2 2021.
- Average EBIAT over 5 years is -$70.5 million, with a median of -$32.8 million recorded in 2021.
- The sharpest move saw EBIAT tumbled 8994.04% in 2021, then surged 2098.21% in 2023.
- Year by year, EBIAT stood at -$34.1 million in 2021, then tumbled by 63.47% to -$55.7 million in 2022, then crashed by 313.42% to -$230.4 million in 2023, then surged by 53.83% to -$106.4 million in 2024, then crashed by 77.55% to -$188.9 million in 2025.
- Business Quant data shows EBIAT for AGL at -$188.9 million in Q4 2025, -$110.2 million in Q3 2025, and -$104.4 million in Q2 2025.